John Hamill Named CFO of Aprea Therapeutics

May 5, 2023

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of John Hamill as chief financial officer. Hamill joins Aprea with more than 30 years of finance and accounting experience.

“Aprea Therapeutics has made substantial progress and is now reaching an exciting inflection point given the advancement of our ATR inhibitor in Phase 1 human clinical trials. I look forward to working closely with John to advance our mission of finding ways to revolutionize the treatment of cancer for patients in need of new therapies,” said Oren Gilad, Ph.D., President, and CEO. “Mr. Hamill is an excellent addition to our team and will help take the company to the next level given his extensive experience in finance, accounting and strategic execution.”

“This is an exciting time to be joining Aprea as it continues its mission to improve the lives of those suffering from cancer,” said Hamill. “I’m excited to work with this team of accomplished and dedicated executives and scientists to advance the pipeline and position the Company for continued success and future growth.”

Hamill joins Aprea with vast financial leadership experience in the pharmaceutical, biopharmaceutical, and clinical research sectors. He brings broad-based experience in financial, administrative and information technology, in addition to his success in completing IPO and follow-on offerings for several pharmaceutical companies.

WittKieffer’s Stephen Brengle and Mindy Steiger led this search.

Read the announcement.

Amanda Krause Named Dean of Arts and Sciences at the University of Evansville

Kelli Shuman Named AVP and CHRO of Carnegie Mellon University

CONNECT WITH US

We partner with you to advance your mission by developing impactful leadership through executive search, leadership advisory, and interim leadership solutions.

John Hamill Named CFO of Aprea Therapeutics

Related Articles

Lisa Harrison Named Dean of the Ohio University Patton College of Education

Gwen Perea Warniment Named President and CEO of the LANL Foundation

Amanda Krause Named Dean of Arts and Sciences at the University of Evansville

Kelli Shuman Named AVP and CHRO of Carnegie Mellon University

Tysen Kendig Named VP for University Communications at Carnegie Mellon University

Zebadiah Hall Named Vice President of Inclusion, Access and Belonging at Salisbury University

Neelam Chand Named Sr. Associate VP, Human Resources, for Case Western Reserve University

Andrea Chapdelaine Named President of Connecticut College

Richard Lyons Named Chancellor of UC Berkeley

Sharon Bentley Named Dean of UC Berkeley Wertheim School of Optometry & Vision Science

Lisa Harrison Named Dean of the Ohio University Patton College of Education

Gwen Perea Warniment Named President and CEO of the LANL Foundation

Amanda Krause Named Dean of Arts and Sciences at the University of Evansville

Kelli Shuman Named AVP and CHRO of Carnegie Mellon University

Tysen Kendig Named VP for University Communications at Carnegie Mellon University

Zebadiah Hall Named Vice President of Inclusion, Access and Belonging at Salisbury University

Neelam Chand Named Sr. Associate VP, Human Resources, for Case Western Reserve University

Andrea Chapdelaine Named President of Connecticut College

Richard Lyons Named Chancellor of UC Berkeley

Sharon Bentley Named Dean of UC Berkeley Wertheim School of Optometry & Vision Science

Lisa Harrison Named Dean of the Ohio University Patton College of Education

Gwen Perea Warniment Named President and CEO of the LANL Foundation

CONNECT WITH US